Why did Stryker surge 19% after cutting full-year guidance?

Stryker Corporation's stock experienced a significant 19% increase after the company reduced its full-year organic growth guidance, despite initially facing a 12.3% drop in shares following the news. The company's robust competitive advantages in the operating room, such as the Mako robotic arm and proprietary orthopedic implants, allowed it to maintain growth in orthopedic surgical procedures, even as broader industry growth slowed.

The company's strong cash flow and dividend growth further bolster its valuation, with analysts predicting significant upside potential.